Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Tissue transglutaminase-interleukin-6 axis facilitates peritoneal tumor spreading and metastasis of human ovarian cancer cells.

Oh K, Moon HG, Lee DS, Yoo YB.

Lab Anim Res. 2015 Dec;31(4):188-97. doi: 10.5625/lar.2015.31.4.188. Epub 2015 Dec 22.

2.

Metastasis-associated S100A4 is a specific amine donor and an activity-independent binding partner of transglutaminase-2.

Biri B, Kiss B, Király R, Schlosser G, Láng O, Kőhidai L, Fésüs L, Nyitray L.

Biochem J. 2016 Jan 1;473(1):31-42. doi: 10.1042/BJ20150843. Epub 2015 Oct 20.

PMID:
26487698
3.

miR-19-Mediated Inhibition of Transglutaminase-2 Leads to Enhanced Invasion and Metastasis in Colorectal Cancer.

Cellura D, Pickard K, Quaratino S, Parker H, Strefford JC, Thomas GJ, Mitter R, Mirnezami AH, Peake NJ.

Mol Cancer Res. 2015 Jul;13(7):1095-1105. doi: 10.1158/1541-7786.MCR-14-0466. Epub 2015 May 1.

4.

The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma.

Erdem S, Yegen G, Telci D, Yildiz I, Tefik T, Issever H, Kilicaslan I, Sanli O.

World J Urol. 2015 Oct;33(10):1553-60. doi: 10.1007/s00345-014-1462-7. Epub 2014 Dec 17.

PMID:
25515319
5.

Transglutaminase II/microRNA-218/-181a loop regulates positive feedback relationship between allergic inflammation and tumor metastasis.

Eom S, Kim Y, Kim M, Park D, Lee H, Lee YS, Choe J, Kim YM, Jeoung D.

J Biol Chem. 2014 Oct 24;289(43):29483-505. doi: 10.1074/jbc.M114.603480. Epub 2014 Sep 8.

6.

Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer.

Yakubov B, Chelladurai B, Schmitt J, Emerson R, Turchi JJ, Matei D.

Neoplasia. 2013 Jun;15(6):609-19.

7.

Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells.

Oh K, Ko E, Kim HS, Park AK, Moon HG, Noh DY, Lee DS.

Breast Cancer Res. 2011 Oct 3;13(5):R96. doi: 10.1186/bcr3034.

8.

In vivo evaluation of type 2 transglutaminase contribution to the metastasis formation in melanoma.

Di Giacomo G, Lentini A, Beninati S, Piacentini M, Rodolfo C.

Amino Acids. 2009 Apr;36(4):717-24. doi: 10.1007/s00726-008-0119-5. Epub 2008 Jul 2.

PMID:
18594948
9.

Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function.

Palumbo JS, Barney KA, Blevins EA, Shaw MA, Mishra A, Flick MJ, Kombrinck KW, Talmage KE, Souri M, Ichinose A, Degen JL.

J Thromb Haemost. 2008 May;6(5):812-9. doi: 10.1111/j.1538-7836.2008.02938.x. Epub 2008 Feb 25.

10.

Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.

Verma A, Wang H, Manavathi B, Fok JY, Mann AP, Kumar R, Mehta K.

Cancer Res. 2006 Nov 1;66(21):10525-33.

11.

GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis.

Xu L, Begum S, Hearn JD, Hynes RO.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9023-8. Epub 2006 Jun 6.

12.

Reduction in transglutaminase activity associated with tumour metastasis is due to the presence of an inactive form of the enzyme.

Knight CR, Rees RC, Griffin M.

Biochem Soc Trans. 1990 Aug;18(4):681-2. No abstract available.

PMID:
1980470
13.

Alterations in the distribution and activity of transglutaminase during tumour growth and metastasis.

Barnes RN, Bungay PJ, Elliott BM, Walton PL, Griffin M.

Carcinogenesis. 1985 Mar;6(3):459-63.

PMID:
2858274

Supplemental Content

Loading ...
Support Center